Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | OKI-219 |
| Trade Name | |
| Synonyms | OKI219|OKI 219 |
| Drug Descriptions |
OKI-219 inhibits PIK3CA H1047R, which potentially results in decreased tumor cell proliferation and reduced tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): B163). |
| DrugClasses | PIK3CA inhibitor 27 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Fulvestrant + OKI-219 | Fulvestrant OKI-219 | 0 | 1 |
| Fulvestrant + OKI-219 + PF-07220060 | Fulvestrant OKI-219 PF-07220060 | 0 | 1 |
| Fulvestrant + OKI-219 + Ribociclib | Fulvestrant OKI-219 Ribociclib | 0 | 1 |
| OKI-219 | OKI-219 | 1 | 1 |
| OKI-219 + Trastuzumab | OKI-219 Trastuzumab | 0 | 0 |
| OKI-219 + Trastuzumab + Tucatinib | OKI-219 Trastuzumab Tucatinib | 0 | 1 |